The AKT1 E17K Mutation: A Direct Activator of AKT

How AKT Is Normally Activated

AKT has a pleckstrin-homology (PH) domain that binds the lipid PIP3. When PI3K makes PIP3 at the membrane, AKT is recruited there, changes shape, and is phosphorylated by PDK1 and mTORC2 to become fully active.

PTEN normally keeps PIP3 low, so AKT activity tracks the balance between PI3K and PTEN.

What E17K Changes

The E17K substitution sits in the PH domain and increases its affinity for membrane phosphoinositides, including PIP2. This lets AKT localise to the membrane and be activated even when PI3K output is low.

In effect, E17K uncouples AKT activation from upstream signalling, producing constitutive pathway activity from a single amino-acid change.

Where It Occurs

AKT1 E17K is found in roughly 3 to 6 percent of breast cancers and at lower frequencies in endometrial, ovarian, lung and other cancers. It also occurs as a mosaic mutation in the overgrowth disorder Proteus syndrome.

It tends to be mutually exclusive with PIK3CA mutations and PTEN loss, consistent with all three converging on the same pathway.

Relevance to Treatment

AKT inhibitors such as capivasertib bind the kinase directly, so they can act on E17K-driven signalling. In the CAPItello-291 trial, capivasertib with fulvestrant improved outcomes in hormone-receptor-positive breast cancer with PIK3CA, AKT1 or PTEN alterations.

Some allosteric AKT inhibitors are less effective against E17K because the mutation changes domain interactions, so inhibitor class matters.

Interpretation Notes

An AKT1 E17K call should be read with the variant allele fraction and whether it is likely clonal, alongside the tumour type and any co-alterations.

The mutation is a pathway-activating event; the decision to use an AKT inhibitor rests on the clinical context and approved indications, not the mutation alone.

Key Takeaways

• ·AKT1 E17K increases PH-domain lipid binding, activating AKT without upstream PI3K signals.
• ·It is uncommon but spread across breast, endometrial and other cancers.
• ·It is usually mutually exclusive with PIK3CA mutation and PTEN loss.
• ·ATP-competitive AKT inhibitors such as capivasertib can target E17K-driven signalling.